Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ayala Pharmaceuticals Inc ADXS

Healthcare Biotechnology
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia... see more

Recent & Breaking News (PINL:ADXS)

Advaxis's Scientific Founder to Present on ADXS-HER2 at World Congress on Breast Cancer 2015

GlobeNewswire July 29, 2015

Advaxis Expands Intellectual Property for Lm Technology(TM) Platform in HER2

GlobeNewswire July 21, 2015

Advaxis Appoints Dr. Shelonitda S. Rose as Vice President, Clinical Development

PR Newswire July 8, 2015

Advaxis's President and Chief Executive Officer Daniel J. O'Connor Receives 2015 Ernst & Young Entrepreneur Of The Year® in New Jersey

PR Newswire June 29, 2015

The Wealthy Biotech Trader's New Feature Pick Runs Over 150% After Announcement - Traders are Calling it the Next PPCH 3,200%+ Runner

Accesswire June 25, 2015

Advaxis Provides 2015 Half-Year Review and Outlook

PR Newswire June 25, 2015

Advaxis Selected for Inclusion in Russell Global and Russell 3000® Indexes

PR Newswire June 22, 2015

Advaxis to Hold Business Update Conference Call on June 25, 2015

PR Newswire June 19, 2015

Three Companies with the Ingredients to Follow in the Footsteps of Advaxis (NASDAQ: ADXS)

Accesswire June 16, 2015

Advaxis Submits Special Protocol Assessment Request to FDA for ADXS-HPV Phase 3 Clinical Trial in Cervical Cancer

PR Newswire June 15, 2015

Advaxis's Cancer Immunotherapy Delays Progression of HER2+ Canine Osteosarcoma

PR Newswire June 8, 2015

Advaxis Announces FDA Clearance of Investigational New Drug Application for Phase 2 Study of ADXS-HPV and Incyte's epacadostat for the Treatment of HPV-Associated Early Stage Cervical Cancer

PR Newswire June 1, 2015

Advaxis to Present at the Jefferies 2015 Global Healthcare Conference

GlobeNewswire May 22, 2015

Advaxis Appoints Fred J. Frullo Vice President, Regulatory Affairs

GlobeNewswire May 21, 2015

Advaxis and Sorrento Form Collaboration to Evaluate Combinations of Advaxis's Lm-LLO Immunotherapy Technology and Sorrento's Immunomodulatory Antibodies

GlobeNewswire May 19, 2015

Advaxis Appoints Thomas W. Hare Vice President, Clinical Operations

GlobeNewswire May 6, 2015

Advaxis Announces Closing Public Offering of Common Stock With Gross Proceeds Totaling $53.2 Million

GlobeNewswire May 5, 2015

Sell In May And Go Away? Trades For Your Portfolio (VLTC, ADXS, BOSC, CVEO)

Accesswire May 1, 2015

Advaxis Prices $53 Million Public Offering of Common Stock

GlobeNewswire April 30, 2015

Advaxis Announces Proposed Public Offering of Common Stock

GlobeNewswire April 29, 2015